Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of human vascular cells following gene transfer

ABSTRACT: For further understanding the gene expression profile of human vascular cells following gene transfer in vitro, we have employed whole genome microarray expression profiling as a discovery platform to identify gene families or single genes with the potential to distinguish between responders and non-responders to a particular gene and cell therapy. Human vascular cells from deceased donors were derived and transduced in vitro. Total RNA was isolated from the cells and subjected to microarray analysis using the Agilent technology. Two human donors, with two cell types per donor, were tested, including transduced cells and two different control samples. Technical triplicates were tested for each sample type. Thus, a total of 36 whole genome arrays were processed and analyzed. Expression of candidate genes from this signature will be quantified in the same RNA samples by real-time PCR, allowing further simplified analysis of a large pool of human donors.

ORGANISM(S): Homo sapiens

SUBMITTER: Diana Gershtein

PROVIDER: E-GEOD-31981 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling of human vascular cells following gene transfer

Project description:For further understanding of the gene expression profile of human vascular cells following gene transfer in vitro, we have employed whole genome microarray expression profiling as a discovery platform to identify gene families or single genes with the potential to distinguish between responders and non-responders to a particular gene therapy. Human vascular cells from deseased donors were derived and transduced in vitro. Total RNA was isolated from the cells and subjected to microarray analysis using the Agilent technology.

2011-11-01 | GSE31981 | GEO

Expression data from Chimeric Antigen Receptor (CAR) Expressing T cells

Project description:Human T cells isolated from healthy donors were transduced with non-tonically signaling CARs or tonically signaling CARs, each with CD28z or 4-1BB costimulatory domains

2015-04-09 | GSE65856 | GEO

Expression data from Chimeric Antigen Receptor (CAR) Expressing T cells

Project description:Human T cells isolated from healthy donors were transduced with non-tonically signaling CARs or tonically signaling CARs, each with CD28z or 4-1BB costimulatory domains Human T cells isolated from healthy donors were transduced with non-tonically signaling CARs or tonically signaling CARs, each with CD28z or 4-1BB costimulatory domains

2015-04-09 | E-GEOD-65856 | biostudies-arrayexpress

DNA methylation regulates lineage-specifying genes in the human vascular system.

Project description:This SuperSeries is composed of the following subset Series: GSE32709: DNA methylation regulates lineage-specifying genes in the human vascular system [expression array]. GSE34486: DNA methylation regulates lineage-specifying genes in the human vascular system [methylation array]. Refer to individual Series

2012-04-09 | E-GEOD-34487 | biostudies-arrayexpress

The Proteomic Landscape of in vitro Cultured Endothelial Cells across Vascular Beds

Project description:Blood vessel endothelial cells (EC) display heterogeneity across vascular beds, which is at the bases of organ specificity and anticipated to drive site-specific vascular pathology. It is assessed in vivo using transcriptomics, and in vitro using functional assays, but how proteomes compare across human in vitro cultured ECs remains incompletely characterized. We generated an in-depth human EC proteomic landscape (>8000 proteins) across 6 vascular beds and 2 in vitro models both in steady-state and upon IFNγ-induced inflammation. EC proteomes displayed a high similarity and organ specific proteins were limited. Variation between ECs and donors was mainly based in biological processes underlying proliferation and differentiation. BOECs and HUVECs represented the extremes of proteomic phenotypes. IFNγ responses were highly conserved across cellular sources. Harnessing dynamics in protein abundances we delineated interactor networks of VWF and VE-Cadherin. This EC landscape provides an extensive proteomic addition in studying EC biology and heterogeneity from an in vitro perspective.

2024-07-25 | PXD045899 | Pride

IGR_CamaraClayette_MCL

Project description:We designed a gene profiling experiment to identify genes involved in secondary drug resistance in mantle cell lymphomas (MCL). We obtained paired tissue samples collected before treatment and after relapse or progression. Variations in gene expression between the 2 samples were estimated for 5 patients. For each gene, the mean variation was estimated for patients with a refractory primary tumor and for responders who developed secondary drug resistance. Nine genes of interest were selected on the basis of the magnitude and statistical significance of the variation of expression in responders and non-responders. BMP7 was the only one with significantly increased expression at relapse in patients who developed secondary resistance. Validation of BMP7 as a key gene involved in secondary resistance was performed using cultures of cell line. Incubation of BMP7 with MCL cell lines increased their resistance to Bortezomib and Cytarabine, while inhibition of BMP7 expression by siRNA correlated with increased cell death linked to drug application.

2013-01-17 | E-MTAB-1090 | biostudies-arrayexpress

Effect of Itolizumab on gene expression profiles of patients enrolled in phase 2 psoriasis clinical trial study (Study number: T1hAbâ??CT1â??001â??07).

Project description:Punch biopsies of patients enrolled in phase II clinical trial study was obtained at various time points. Skin biopsies from 16 responders and 8 non responders and partial responders, chosen after the completion of clinical trial, was evaluated before Itolizumab treatment (Day 1) and at Day 57. Responders had a PASI improvement >75% while non responders had a PASI improvement <60%. The gene expression values at Day 57 were normalised with values obtained at Day 1 of the respective patient sample. The genes with a minimum fold change of 1.8 spontaneously clustered into predominantly responders and non responders. Agilent Custom Human Gene Expression 8X15k (AMADID: 16332) designed by Genotypic Technology Private Limited .

2016-09-01 | E-GEOD-72246 | biostudies-arrayexpress

Affymetrix SNP array data for human skin keratinocytes

Project description:Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from human skin keratinocytes derived from healthy donors, as well as from telomerase immortalised human skin keratinocytes (N/TERT), transduced with mock, EGFP, or EGFP-GLI2DeltaN transgenes to compare chromosomal ploidy status.

2012-02-28 | GSE36105 | GEO

Expression data from colonic biopsy samples of infliximab treated ulcerative colitis patients

Project description:A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. Genes affected are primarily involved with inflammatory response, cell-mediated immune responses, and cell-to-cell signaling. Infliximab non-responders had a molecular phenotype that closely resembled that of untreated patients with UC. Unlike responders, non-responders do not effectively modulate TH1, TH2, and TH17 pathways. Gene expression can differentiate placebo and infliximab responders. Patients with moderate-to-severe, active UC were treated with infliximab or placebo at weeks 0, 2, 6 and every 8 weeks thereafter. Biopsy samples (n=113) were collected from 48 patients at baseline, weeks 8 and 30 for RNA extraction and microarray analysis.

2011-07-21 | E-GEOD-23597 | biostudies-arrayexpress

Crenigacestat inhibits osteogenic differentiation of human valve interstitial cells and seems promising for treatment of cardiovascular calcification

Project description:Vascular calcification is common pathology various forms of which presented in the half of humans. Calcific aortic valve disease (CAVD) is one of the most dangerous forms of vascular calcification. Despite high mortality there is no target therapy against CAVD. Thus, we tested crenigacestat (LY3039478), inhibitor of Notch-signaling, and shRNA against RBPJk for inhibition of osteogenic differentiation of velve intersticial cells (VICs) in vitro. Both of them effectivelly enhibited osteogenic differentiation and we performed proteomics analysis do describe molecular mechanisms of their effect. Presented dataset contain results of shotgun proteomics analysis with ion mobility in TimsToF Pro instrument (in DDA PASEF mode) of VICs in classic osteogenic medium (OM) and OM supplemented with crenigacestat, DMSO or shCSL.

2022-10-04 | PXD029632 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data